, Volume 39, Supplement 4, pp 29–40 | Cite as

Systemic and Coronary Haemodynamics and Pharmacodynamics of Enalapril and Enalaprilat in Congestive Heart Failure

  • Kanu Chatterjee
  • Teresa De Marco
Section 2


Enalapril is an effective angiotensin-converting enzyme (ACE) inhibitor which produces salutary, beneficial haemodynamic effects in patients with congestive heart failure. Enalapril also produces beneficial neurohumoral changes, as well as improving abnormal coronary haemodynamics and myocardial energetics that are frequently encountered in these patients. Administration of enalapril once or twice daily appears to be quite effective during maintenance therapy in patients with chronic congestive heart failure.


Congestive Heart Failure Captopril Enalapril Angiotensin Converting Enzyme Inhibitor Plasma Renin Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, et al. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by oral angiotensin converting enzyme inhibitor. Circulation 61: 931–937, 1980PubMedCrossRefGoogle Scholar
  2. Brunner HR, Waeber B, Nussberger J, Schaller MD. Long term clinical experiences with enalapril in essential hypertension. Journal of Hypertension 1(Suppl. 1): 103–107, 1983PubMedGoogle Scholar
  3. Chatterjee K, Viquerat CE, Daly P. Neurohumoral abnormalities in heart failure. Heart Failure 1: 69–83, 1985Google Scholar
  4. Clauser E, Gonzales MF, Bouhnik J, Corvol P, Menard J. The effects of converting enzyme inhibitors on plasma angioten-sinogen and plasma aldosterone in sodium-depleted rats. Journal of Hypertension 1(Suppl. 1): 37–40, 1983PubMedGoogle Scholar
  5. Cody RJ. Clinical and hemodynamic experience with enalapril in congestive heart failure. American Journal of Cardiology 55: 36A–40A, 1985PubMedCrossRefGoogle Scholar
  6. Creager MA, Massie BM, Faxon DP, Friedman SD, Kramer BL, et al. Acute and long term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. Journal of the American College of Cardiology 6: 163–170, 1985PubMedCrossRefGoogle Scholar
  7. De Marco T, Chatterjee K, Rouleau JL, Parmley WW. Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy. American Heart Journal 115: 809–815, 1988PubMedCrossRefGoogle Scholar
  8. De Marco T, Daly PA, Liu M, Kayser S, Parmley WW, et al. Enalaprilat, a new parenteral angiotensin converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure. Journal of the American College of Cardiology 9: 1131–1138, 1987PubMedCrossRefGoogle Scholar
  9. DiCarlo L, Chatterjee K, Parmley WW, Swedberg K, Atherton B, et al. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic evaluations. Journal of the American College of Cardiology 2: 865–871, 1983PubMedCrossRefGoogle Scholar
  10. Dickstein K, Soyland E, Gundersten T, Abrahamsen AM, Kjekshus J. Acute and chronic hemodynamic effects of enalapril in congestive heart failure. International Journal of Cardiology 6: 445–456, 1984PubMedCrossRefGoogle Scholar
  11. Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. American Journal of Cardiology 53: 105–108, 1984PubMedCrossRefGoogle Scholar
  12. Fitz A, Lawton W, Reimer J, Nelson G. The effect of enalapril, a non-thiol converting enzyme inhibitor on vasoactive factors in hypertension. Clinical Research 30: 775A, 1982Google Scholar
  13. Fitzpatrick D, Nicholls MG, Ikram H, Espiner EA. Hemodynamic hormonal and electrolyte effects of enalapril in heart failure. British Heart Journal 50: 163–169, 1983PubMedCrossRefGoogle Scholar
  14. Foud FM, Tarazi RC, Bravo EL, Textor SE. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting enzyme inhibitor MK-421 (enalapril). Hypertension 6: 167–174, 1984Google Scholar
  15. Fraser AG, Henderson AH, Lewis MJ, Mulligan IP, Tirlapur VG. Acute and chronic effects of enalapril during rest and exercise in congestive heart failure. British Journal of Clinical Pharmacology 20: 263P–264P, 1985Google Scholar
  16. Fregly MJ, Fater DC. Effect of the angiotensin converting enzyme inhibitor MK-421 on experimentally induced drinking. Physiologist 24: 12, 1981Google Scholar
  17. Fruncillo RJ, Roccl Jr ML, Shepley K, Clementi RA, Derita R, et al. Enalaprilat accumulates after chronic enalapril dosing in renal failure. Clinical Pharmacology and Therapeutics 37: 197, 1985Google Scholar
  18. Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, et al. Effect of N-[(s)-l-carboxy-3-phenylpropyl]-L-ALA-L-PRO and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. Journal of Pharmacology and Experimental Therapeutics 216: 522–557, 1981Google Scholar
  19. Guidicelli JF, Berdeaux A, Edouard A, Richer C, Jacolot D. The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects. British Journal of Clinical Pharmacology 20: 211–218, 1985CrossRefGoogle Scholar
  20. Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–458, 1980PubMedCrossRefGoogle Scholar
  21. Hodsman GP, Brown JJ, Cummings AMM, Davies DL, East BW, et al. Enalapril in the treatment of hypertension with renal artery stenosis. British Medical Journal 287: 1413–1417, 1983PubMedCrossRefGoogle Scholar
  22. Howlett DR, Longman SD. Effects of chronic enalapril (MK-421) treatment on the renin-angiotensin system in the sodium depleted rat. British Journal of Pharmacology 79: 323, 1983Google Scholar
  23. Jackson B, Johnson CL. Angiotensin converting enzyme inhibition by MK421: a potent long acting oral agent. Australian and New Zealand Journal of Medicine 12: 355–360, 1984Google Scholar
  24. Johnston CL, Jackson BJ, Larmour I, Cubella R, Casley D. Plasma enalapril levels and hormonal effects after short and long-term administration in essential hypertension. British Journal of Clinical Pharmacology 18(Suppl. 2): 233S–239S, 1984PubMedCrossRefGoogle Scholar
  25. Kelley J, Doyle G, Donohoe J, Laher M, Vandenburg MJ, et al. The pharmacokinetic profile of enalaprilat in normal subjects and patients with renal impairment. British Journal of Clinical Pharmacology 18: 274, 1984Google Scholar
  26. Kelley J, Doyle G, Donohoe J, Laher M, Vandenberg MJ, et al. Chronic dose pharmacokinetics of enalapril in renal impairment. British Journal of Clinical Pharmacology 20: 264–265, 1985Google Scholar
  27. Larochelle P, Gutkowska J, Schiffrin E, Kuchel O, Hamet P, et al. Effect of enalapril on renin, angiotensin converting enzyme activity, aldosterone and prostaglandins in patients with hypertension. Clinical and Investigative Medicine 8: 197–201, 1985PubMedGoogle Scholar
  28. Levine TB, Oliver MT, Garberg V, Shyarkey SW, Cohn JN. Hemodynamic and clinical response to enalapril, a long-acting converting enzyme inhibitor in patients with congestive heart failure. Circulation 69: 548–553, 1984PubMedCrossRefGoogle Scholar
  29. McCaa RE, Gillespie JB. Effects of captopril and enalapril on sodium excretion and blood pressure in sodium deficient dogs. Federation Proceedings 43: 1336–1341, 1984PubMedGoogle Scholar
  30. Odya LE, Wilgis FP, Walker JF, Oparil S. Immune reactive bradykinin and [DES-ARG9]-bradykinin in low renin essential hypertension before and after treatment with enalapril (MK421). Journal of Laboratory and Clinical Medicine 102: 714–721, 1983PubMedGoogle Scholar
  31. Oparil S, Horton R, Wilkins LH, Irvin J, Hammett DK, et al. Antihypertensive effect of enalapril (MK421) in low renin essential hypertension: role of vasodilator prostaglandins. Clinical Research 31: 538A, 1983Google Scholar
  32. Ryan MJ, Boucher DM, Cohen DM, Essenburg AD, Major TC, et al. Antihypertensive effects of C1-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor. Journal of Pharmacology and Experimental Therapeutics 228: 312–318, 1984PubMedGoogle Scholar
  33. Sanchez RA, Marco E, Gilbert HB, Raffaele P, Brito M, et al. Natriuretic effect and changes in renal hemodynamics induced by enalapril in essential hypertension. Drugs 30(Suppl. 1): 49–58, 1985PubMedCrossRefGoogle Scholar
  34. Schiffrin EL, Gutkowska J, Thibault G, Genest J. Effect of enalapril (MK-421) an orally active angiotensin-I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin-E2, and kallikrein excretion in conscious rats. Canadian Journal of Physiology and Pharmacology 62: 116–123, 1984PubMedCrossRefGoogle Scholar
  35. Schwartz JB, Taylor A, Abernathy D, O’Meara M, Farmer J, et al. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. Journal of Cardiovascular Pharmacology 7: 767–776, 1985PubMedCrossRefGoogle Scholar
  36. Sweet CS, Arbegast PT, Gaul SL, Blaine EH, Gross DM. Relationship between angiotensin 1 blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. European Journal of Pharmacology 76: 167–176, 1981PubMedCrossRefGoogle Scholar
  37. Sweet LS, Ulm EH. Enalapril. In Scriabine A (Ed.) New drugs annual, cardiovascular drugs, Vol. 2, pp. 1–17, Raven Press, New York, 1984Google Scholar
  38. Takata Y, Di Nicolantonio R, Mendelsohn FAO, Hutchinson JS, Doyle AE. A comparison of the activity of the angiotensin converting enzyme inhibitors sq. 14225, SA 446, and MK421. Clinical and Experimental Pharmacology and Physiology 10: 131–145, 1983PubMedCrossRefGoogle Scholar
  39. Till AE, Gomez HJ, Hichens M, Bolognese JA. Pharmacokinetics of repeated oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharmaceutics and Drug Disposition 5: 273–280, 1984CrossRefGoogle Scholar
  40. Todd PA, Heel RC. Enalapril: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986PubMedCrossRefGoogle Scholar
  41. Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, et al. Enalapril maleate and a lysing analogue (MK-521): disposition in man. British Journal of Pharmacology 14: 357–362, 1982CrossRefGoogle Scholar
  42. Vlasses PH, Larijani GE, Conner DP, Ferguson RK. Enalapril, a non-sulfhydryl angiotensin-converting enzyme inhibitor. Clinical Pharmacology 4: 27–40, 1985Google Scholar
  43. Wilkes BM. Evidence for a vasodepressor effect of the angiotensin-converting enzyme inhibitor MK421 (enalapril), independent of blockade of angiotensin II formation. Journal of Cardiovascular Pharmacology 6(6): 1036–1042, 1984PubMedGoogle Scholar

Copyright information

© ADIS Press Limited 1990

Authors and Affiliations

  • Kanu Chatterjee
    • 1
  • Teresa De Marco
    • 1
  1. 1.Division of CardiologyUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations